Aclarion (NASDAQ:ACON – Get Free Report) and SeaStar Medical (NASDAQ:ICU – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, risk and earnings.
Institutional and Insider Ownership
7.5% of Aclarion shares are held by institutional investors. Comparatively, 1.7% of SeaStar Medical shares are held by institutional investors. 0.0% of Aclarion shares are held by insiders. Comparatively, 0.7% of SeaStar Medical shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares Aclarion and SeaStar Medical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Aclarion | -10,320.51% | -54.41% | -51.71% |
| SeaStar Medical | -828.62% | -146.29% | -96.48% |
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Aclarion | $80,000.00 | 108.55 | -$7.23 million | ($9.03) | -0.39 |
| SeaStar Medical | $1.23 million | 10.18 | -$12.15 million | ($4.80) | -0.65 |
Aclarion has higher earnings, but lower revenue than SeaStar Medical. SeaStar Medical is trading at a lower price-to-earnings ratio than Aclarion, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Aclarion has a beta of 1.22, meaning that its stock price is 22% more volatile than the S&P 500. Comparatively, SeaStar Medical has a beta of -1.05, meaning that its stock price is 205% less volatile than the S&P 500.
Analyst Recommendations
This is a summary of recent recommendations and price targets for Aclarion and SeaStar Medical, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Aclarion | 1 | 0 | 1 | 0 | 2.00 |
| SeaStar Medical | 1 | 0 | 1 | 0 | 2.00 |
Aclarion presently has a consensus price target of $7.50, suggesting a potential upside of 112.46%. SeaStar Medical has a consensus price target of $8.00, suggesting a potential upside of 155.59%. Given SeaStar Medical’s higher probable upside, analysts clearly believe SeaStar Medical is more favorable than Aclarion.
Summary
Aclarion beats SeaStar Medical on 7 of the 12 factors compared between the two stocks.
About Aclarion
Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.
About SeaStar Medical
SeaStar Medical Holding Corporation, a medical device company, develops a platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers inflammatory response to fend off infections and repair damaged tissue in the body. It is also developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure; myocardial stunning in end stage renal disease; and hepatorenal syndrome. The company is headquartered in Denver, Colorado.
Receive News & Ratings for Aclarion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclarion and related companies with MarketBeat.com's FREE daily email newsletter.
